https://scholars.lib.ntu.edu.tw/handle/123456789/597548
標題: | Managing the adverse effects related to immune checkpoint inhibitors | 作者: | Kuo H.-H. WEI-WU CHEN |
關鍵字: | Immune checkpoint inhibitors; Immune-related adverse effect | 公開日期: | 2018 | 出版社: | Taiwan Nurses Association | 卷: | 65 | 期: | 3 | 起(迄)頁: | 88-95 | 來源出版物: | Journal of Nursing | 摘要: | Immune checkpoint inhibitors (ICIs) have become the new posterchild of cancer treatment in recent years largely due to their impressive clinical efficacy. Drugs targeting cytotoxic T- lymphocyteassociated antigen 4 (CTLA-4) and programmed cell death-1 (PD-1) antibodies, e.g., ipilimumab (Yervoy?), pembrolizumab (Keytruda?), and nivolumab (Opdivo?) reinvigorate cytotoxic T cells to kill cancer cells in patients. Despite the impressive clinical benefits, ICIs may induce immunerelated adverse events (irAE) of the skin, gastrointestinal tract, liver, endocrine, and lung with a wide spectrum of severity. Rare but severe irAEs of critical organs such as the heart and central nervous system have also been reported. Clinical practitioners must recognize the early signs and symptoms of irAE as well as related management strategies. ? 2018 Lippincott Williams and Wilkins. All rights reserved. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85047783432&doi=10.6224%2fJN.201806-65%283%29.12&partnerID=40&md5=03ea03f317279bc9e56f641ad0d1d628 https://scholars.lib.ntu.edu.tw/handle/123456789/597548 |
ISSN: | 0047-262X | DOI: | 10.6224/JN.201806-65(3).12 | SDG/關鍵字: | CTLA4 protein, human; cytotoxic T lymphocyte antigen 4; ipilimumab; monoclonal antibody; nivolumab; pembrolizumab; programmed death 1 receptor; antagonists and inhibitors; human; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; CTLA-4 Antigen; Humans; Ipilimumab; Programmed Cell Death 1 Receptor |
顯示於: | 醫學院附設醫院 (臺大醫院) |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。